ECSP17019893A - Tratamientos médicos a base de anamorelina - Google Patents

Tratamientos médicos a base de anamorelina

Info

Publication number
ECSP17019893A
ECSP17019893A ECIEPI201719893A ECPI201719893A ECSP17019893A EC SP17019893 A ECSP17019893 A EC SP17019893A EC IEPI201719893 A ECIEPI201719893 A EC IEPI201719893A EC PI201719893 A ECPI201719893 A EC PI201719893A EC SP17019893 A ECSP17019893 A EC SP17019893A
Authority
EC
Ecuador
Prior art keywords
anamorelin
therapeutically effective
medical treatments
based medical
patient
Prior art date
Application number
ECIEPI201719893A
Other languages
English (en)
Inventor
Elizabeth Duus
John Friend
William Mann
Ming Lu
Enrico Baroni
Ruben Giorgino
William Polvino
Suzan Allen
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17019893(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of ECSP17019893A publication Critical patent/ECSP17019893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos de tratamiento de afecciones relacionadas con el cáncer usando anamorelina. La modalidad principal se relaciona con la afección única de pacientes que la definen mediante el tratamiento de la caquexia en un paciente humano con cáncer, que comprende la administración a dicho paciente de una cantidad terapéuticamente efectiva de anamorelina durante un período terapéuticamente efectivo, y la sorprendente capacidad observada de la anamorelina de aumentar la masa corporal magra de esta población.
ECIEPI201719893A 2014-09-04 2017-03-30 Tratamientos médicos a base de anamorelina ECSP17019893A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
ECSP17019893A true ECSP17019893A (es) 2017-05-31

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201719893A ECSP17019893A (es) 2014-09-04 2017-03-30 Tratamientos médicos a base de anamorelina

Country Status (44)

Country Link
US (5) US9675600B2 (es)
EP (2) EP3188599B1 (es)
JP (3) JP6356907B2 (es)
KR (3) KR102307275B1 (es)
CN (5) CN113577074A (es)
AP (1) AP2017009772A0 (es)
AR (1) AR103118A1 (es)
AU (1) AU2015312231B2 (es)
BR (1) BR112017003552A2 (es)
CA (1) CA2959158A1 (es)
CL (1) CL2017000494A1 (es)
CO (1) CO2017003263A2 (es)
CR (1) CR20170121A (es)
CY (1) CY1122746T1 (es)
DK (1) DK3188599T3 (es)
DO (1) DOP2017000055A (es)
EA (1) EA035578B1 (es)
EC (1) ECSP17019893A (es)
ES (1) ES2761777T3 (es)
GE (1) GEP20186939B (es)
HR (1) HRP20192345T1 (es)
HU (1) HUE046894T2 (es)
IL (1) IL250692B (es)
JO (1) JO3541B1 (es)
LT (1) LT3188599T (es)
MA (1) MA40607B1 (es)
MD (1) MD4710C1 (es)
ME (1) ME03597B (es)
MX (1) MX361741B (es)
MY (1) MY187167A (es)
NI (1) NI201700024A (es)
PE (1) PE20171109A1 (es)
PH (1) PH12017500392A1 (es)
PL (1) PL3188599T3 (es)
PT (1) PT3188599T (es)
RS (1) RS59751B1 (es)
SG (1) SG11201701567UA (es)
SI (1) SI3188599T1 (es)
SV (1) SV2017005400A (es)
TN (1) TN2017000040A1 (es)
TW (1) TWI639429B (es)
UA (1) UA120765C2 (es)
UY (1) UY36286A (es)
WO (1) WO2016036598A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
CN113577074A (zh) 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗
WO2020231843A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
JP2022546162A (ja) 2019-08-30 2022-11-04 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法
TW202128165A (zh) 2019-10-24 2021-08-01 日商東麗股份有限公司 惡病質之治療劑或預防劑
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2854810A4 (en) 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
CN113577074A (zh) 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗

Also Published As

Publication number Publication date
CN107375285A (zh) 2017-11-24
EP3188599A1 (en) 2017-07-12
TWI639429B (zh) 2018-11-01
KR20170047372A (ko) 2017-05-04
KR101881264B1 (ko) 2018-07-23
MD4710B1 (ro) 2020-09-30
US20170296526A1 (en) 2017-10-19
UA120765C2 (uk) 2020-02-10
JP6923486B2 (ja) 2021-08-18
CN113577073A (zh) 2021-11-02
EP3188599A4 (en) 2017-10-11
GEP20186939B (en) 2018-12-25
US20160067236A1 (en) 2016-03-10
UY36286A (es) 2016-02-29
MX2017002825A (es) 2017-09-28
EP3188599B1 (en) 2019-10-02
CA2959158A1 (en) 2016-03-10
CL2017000494A1 (es) 2017-09-15
JP2017526695A (ja) 2017-09-14
KR102307275B1 (ko) 2021-09-30
JP6356907B2 (ja) 2018-07-11
SV2017005400A (es) 2017-04-20
MX361741B (es) 2018-12-14
AR103118A1 (es) 2017-04-19
JP2018154655A (ja) 2018-10-04
SI3188599T1 (sl) 2020-02-28
EP3590338A3 (en) 2020-03-18
KR20210035923A (ko) 2021-04-01
US10278964B2 (en) 2019-05-07
PL3188599T3 (pl) 2020-06-01
PT3188599T (pt) 2020-01-15
MA40607B1 (fr) 2019-11-29
JP2021080281A (ja) 2021-05-27
US10894041B2 (en) 2021-01-19
PH12017500392B1 (en) 2017-07-17
IL250692A0 (en) 2017-04-30
MY187167A (en) 2021-09-07
NZ729673A (en) 2023-09-29
MD4710C1 (ro) 2021-04-30
PE20171109A1 (es) 2017-08-07
CN109172575A (zh) 2019-01-11
AP2017009772A0 (en) 2017-02-28
CY1122746T1 (el) 2021-03-12
US11723902B2 (en) 2023-08-15
US20190175574A1 (en) 2019-06-13
KR102234319B1 (ko) 2021-04-01
TW201613587A (en) 2016-04-16
BR112017003552A2 (pt) 2017-12-05
US20240024303A1 (en) 2024-01-25
US20210093627A1 (en) 2021-04-01
ES2761777T3 (es) 2020-05-21
LT3188599T (lt) 2019-12-10
AU2015312231B2 (en) 2017-10-19
CR20170121A (es) 2017-07-17
IL250692B (en) 2019-05-30
CO2017003263A2 (es) 2017-07-28
SG11201701567UA (en) 2017-03-30
DOP2017000055A (es) 2017-08-15
ME03597B (me) 2020-07-20
CN107205389A (zh) 2017-09-26
KR20180085047A (ko) 2018-07-25
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
PH12017500392A1 (en) 2017-07-17
MD20170025A2 (ro) 2017-07-31
CN113577074A (zh) 2021-11-02
JP7044918B2 (ja) 2022-03-30
WO2016036598A1 (en) 2016-03-10
NI201700024A (es) 2017-07-18
AU2015312231A1 (en) 2017-03-23
EA035578B1 (ru) 2020-07-09
HRP20192345T1 (hr) 2020-03-20
EP3590338A2 (en) 2020-01-08
TN2017000040A1 (en) 2018-07-04
HUE046894T2 (hu) 2020-04-28
RS59751B1 (sr) 2020-02-28
JO3541B1 (ar) 2020-07-05
US9675600B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
TWD196868S (zh) 超音波治療手持件
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2020001727A (es) Terapia de combinacion.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2021002322A (es) Nuevos metodos.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2019003751A (es) Proteina terapeutica.
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
ZA202006986B (en) Dantrolene formulations and methods of their use
GT201700041A (es) Tratamientos médicos a base de anamorelina
EA201991866A1 (ru) Комбинированная терапия
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
Fabiny Ask the doctor. I recently took antibiotics to treat an oral infection and as a result developed a vaginal yeast infection. Can I treat it myself, and what are the most effective options?
RU2015109209A (ru) Способ количественной оценки зубочелюстно-лицевых аномалий